We’re reader-supported and may be paid when you visit links to partner sites. We don’t compare all products in the market, but we’re working on it!
Adaptive Biotechnologies Corporation is a biotechnology business with stocks listed in the US. Adaptive Biotechnologies shares (ADPT) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was US$39.75 – an increase of 4.3% over the previous week. Here's how to invest if you're based in Australia.
Our top pick for
US stocks
Our top pick for
ETF investing
Our top pick for
Overall broker
| 52-week range | US$29.735 - US$71.25 |
|---|---|
| 50-day moving average | US$35.312 |
| 200-day moving average | US$38.4321 |
| Target price | US$56.67 |
| PE ratio | N/A |
| Dividend yield | N/A (0%) |
| Earnings per share (TTM) | US$-1.244 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
Historical closes compared with the last close of $39.75
| 1 week (2021-09-09) | 3.65% |
|---|---|
| 1 month (2021-08-19) | 32.41% |
| 3 months (2021-06-18) | 0.76% |
| 6 months (2021-03-19) | -5.11% |
| 1 year (2020-09-18) | -14.24% |
|---|---|
| 2 years (2019-09-19) | 1.87% |
| Revenue TTM | US$133.4 million |
|---|---|
| Gross profit TTM | US$-40,220,000 |
| Return on assets TTM | -11.41% |
| Return on equity TTM | -28% |
| Profit margin | -128.33% |
| Book value | 4.928 |
| Market capitalisation | US$5.6 billion |
TTM: trailing 12 months
There are currently 4.0 million Adaptive Biotechnologies shares held short by investors – that's known as Adaptive Biotechnologies's "short interest". This figure is 8.4% down from 4.4 million last month.
There are a few different ways that this level of interest in shorting Adaptive Biotechnologies shares can be evaluated.
Adaptive Biotechnologies's "short interest ratio" (SIR) is the quantity of Adaptive Biotechnologies shares currently shorted divided by the average quantity of Adaptive Biotechnologies shares traded daily (recently around 568752.98295455). Adaptive Biotechnologies's SIR currently stands at 7.04. In other words for every 100,000 Adaptive Biotechnologies shares traded daily on the market, roughly 7040 shares are currently held short.
However Adaptive Biotechnologies's short interest can also be evaluated against the total number of Adaptive Biotechnologies shares, or, against the total number of tradable Adaptive Biotechnologies shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Adaptive Biotechnologies's short interest could be expressed as 0.03% of the outstanding shares (for every 100,000 Adaptive Biotechnologies shares in existence, roughly 30 shares are currently held short) or 0.043% of the tradable shares (for every 100,000 tradable Adaptive Biotechnologies shares, roughly 43 shares are currently held short).
A SIR below 10% would generally be considered to indicate a fairly optimistic outlook for the share price, with fewer people currently willing to bet against Adaptive Biotechnologies.
Find out more about how you can short Adaptive Biotechnologies stock.
We're not expecting Adaptive Biotechnologies to pay a dividend over the next 12 months.
Over the last 12 months, Adaptive Biotechnologies's shares have ranged in value from as little as US$29.735 up to US$71.25. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Adaptive Biotechnologies's is 0.2561. This would suggest that Adaptive Biotechnologies's shares are less volatile than average (for this exchange).
Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunoSEQ research service and kit that is used to answer translational research questions, as well as to discover new prognostic and diagnostic signals; and T-Detect COVID for the confirmation of past COVID-19 infection. It also provides clonoSEQ diagnostic tests, which include immunosequencing services for use in the detection and monitoring of minimal residual disease in patients with select blood cancers; and immunoSEQ T-MAP COVID for vaccine developers and researchers to measure the T-cell immune response to vaccines. In addition, the company offers a pipeline of clinical products and services that are used for the diagnosing, monitoring, and treatment of diseases, such as cancer, autoimmune conditions, and infectious diseases. It serves the life sciences research, clinical diagnostics, and drug discovery customers. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. It also has a research collaboration with Curebase, Inc. to enhance patient participation in clinical studies. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
Shares in the telecoms operator have jumped nearly 40% over the last 12 months.
This guide will show you step-by-step instructions on how to buy the IRON Titanium Token (TITAN) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Wabi (WABI) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Cindicator (CND) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the MonaCoin (MONA) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Bluzelle (BLZ) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Whitecoin (XWC) token as well as a list of exchanges you can trade it on.
This guide will show you step-by-step instructions on how to buy the Storj (STORJ) token as well as a list of exchanges you can trade it on.
Despite the good news, Qantas shares closed flat following the announcement, but that could change in the coming weeks.
Shares in the lithium producer are up five-fold over the last 12 months.
